Finally, in our opinion, definitive treatment should be provided early after a partial or near complete response to BRAF/MEK inhibitors and adapted to the anatomical location and volume of the tumor remnants as well as their surgical accessibility. The gene discussed is BRAF; the disease is neoplasm.